Atopix Therapeutics Limited is a clinical stage biotechnology company developing novel treatments for Th2-mediated eosinophilic asthma
OC459 is a low dose, once-a-day drug with an excellent safety profile demonstrated in over 800 subjects
CRTH2 receptor and its role in allergy
